The Yahoo Finance Live team discusses the latest moves by activist investors of companies, including Union Pacific, Salesforce, and Disney. Read More...
Benzinga
Why Reata Pharmaceuticals Shares Are Falling Monday?
According to various reports, the FDA’s neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. Dunn presided over the controversial approval of Biogen Inc’s (NASDAQ: BIIB) Alzheimer’s disease treatment, Aduhelm (aducanumab). Dunn, 53, is retiring from the agency to “explore other opportunities,” according to an internal FDA email. Dunn notified agency officials Friday, according to a person with knowledge of the situation. Reata Pharmaceuticals Inc
